First-Line FDA-Approved Medications for Weight Loss

Introduction to Weight Loss Medications

The American College of Cardiology recommends Semaglutide (2.4 mg) as the most effective first-line FDA-approved medication for weight loss, demonstrating superior efficacy with mean weight loss of up to 21% at 72 weeks 1

The American Gastroenterological Association indicates that Liraglutide (Saxenda) is approved at 3.0 mg daily dose for weight management 2
The American Diabetes Association suggests that Phentermine-topiramate (Qsymia) is a fixed-dose combination targeting multiple signaling pathways 2
The American Diabetes Association also recommends Naltrexone-bupropion (Contrave) as a combination that activates POMC neurons in the arcuate nucleus 2
The American Gastroenterological Association notes that Orlistat (Xenical/Alli) blocks absorption of about 30% of ingested fat 2

The National Institute of Diabetes and Digestive and Kidney Diseases indicates that FDA-approved weight loss medications are indicated for individuals with BMI ≥30 kg/m² or BMI ≥27 kg/m² with one or more obesity-associated comorbid conditions (e.g., type 2 diabetes, hypertension, dyslipidemia) 4, 1
The American Heart Association recommends that all medications should be used as adjuncts to reduced-calorie eating pattern 5
The American Heart Association also suggests that all medications should be used as adjuncts to increased physical activity 5
The American College of Cardiology indicates that all medications should be used as adjuncts to behavioral counseling 1

The Endocrine Society notes that Tirzepatide has a weight loss effectiveness of ~21% weight loss at 72 weeks 1
The American Gastroenterological Association suggests that Phentermine-topiramate has variable weight loss 2
The American Diabetes Association indicates that Naltrexone-bupropion has moderate weight loss 2
The American Gastroenterological Association notes that Orlistat has modest weight loss 2

The American College of Cardiology recommends Semaglutide 2.4 mg weekly or Tirzepatide as preferred first-line options due to superior efficacy and cardiovascular benefits 1
The American Gastroenterological Association suggests Phentermine-topiramate or Naltrexone-bupropion as alternative first-line options 2
The American Gastroenterological Association notes that Orlistat is a budget-conscious option, available over-the-counter at lower dose (Alli) 2

The American Diabetes Association recommends assessing efficacy and safety at least monthly for the first 3 months and quarterly thereafter 3
The American Diabetes Association suggests continuing medication beyond reaching weight loss goals to maintain health benefits 5
The American Diabetes Association indicates that medication should be discontinued or changed if <5% weight loss after 3 months of treatment 6

The American Heart Association notes that sudden discontinuation often results in weight regain and worsening of cardiometabolic risk factors 5
The American College of Cardiology indicates that Medicare currently excludes coverage of FDA-approved antiobesity medications for obesity alone, creating access barriers 7
The American College of Cardiology also notes that global shortages of GLP-1 receptor agonists may affect availability 7

The American Diabetes Association recommends reviewing concomitant medications that may promote weight gain (antipsychotics, some antidepressants, glucocorticoids, β-blockers) 5, 6
The American Diabetes Association suggests not using medications without concurrent lifestyle modifications 1